For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

A next-generation obesity shot from Eli Lilly and Co. helped patients lose almost a quarter of their body weight, potentially ...

Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...